CHJ.89896
Methotrexate hydrate
--
--
Ordering
Available Variants1 mL
CHJ.89896-1mL
Price
€296.80
Available – Dispatch in 14 days
25 mg
CHJ.89896-25mg
Price
€61.20
Available – Dispatch in 14 days
100 mg
CHJ.89896-100mg
Price
€162.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
1 mL | CHJ.89896-1mL | €296.80 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHJ.89896-25mg | €61.20 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
100 mg | CHJ.89896-100mg | €162.40 |
≥99.0% (sum of enantiomers, HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C20H22N8O5 · xH2O |
|---|---|
| CAS Number | 133073-73-1 |
| Molecular Weight | 454.44 (anhydrous basis) |
| PubChem Substance ID | 329748247 |
| UNSPSC Code | 12352202 |
| NACRES | NA.77 |
| EC Number | 200-413-8 |
| MDL number | MFCD00150847 |
Safety Information Handling visibility
| pictograms |
GHS06
GHS08
 GHS06,GHS08
|
|---|---|
| signalword | Danger |
| hcodes | H301,H341,H360D,H372 |
| pcodes | P202 - P260 - P264 - P280 - P301 + P310 - P405 |
| Hazard Classifications | Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1 |
| target_organs | Liver,Bone marrow |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges |
Technical Overview & Applications Use-case context
Methotrexate hydrate, with a CAS number of 9007-34-5, is a chemotherapeutic agent that has been widely used in the treatment of various types of cancer, including breast, lung, and leukemia, as well as autoimmune diseases such as rheumatoid arthritis and psoriasis. The mechanism of action of methotrexate involves the inhibition of dihydrofolate reductase, an enzyme essential for DNA synthesis and cell replication. By blocking this enzyme, methotrexate prevents cancer cells from proliferating and ultimately leads to cell death. Methotrexate hydrate is typically administered orally or intravenously, and its dosage and administration schedule are carefully tailored to the individual patients needs and medical condition. The efficacy and safety of methotrexate hydrate have been extensively studied, and it remains a crucial component of many cancer treatment regimens and disease management strategies. Its use requires careful monitoring due to potential side effects.
